For laboratory research use only. This page summarises published scientific literature on Tesamorelin in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.
Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption
Table of Contents
- 2. Molecular structure — full-length GHRH vs CJC-1295
- 3. GHRH receptor pharmacology
- 4. Pharmacokinetics
- 5. HIV-lipodystrophy pivotal trials
- 8. Cognitive and CNS research
- 10. Pulsatility preservation vs CJC-1295 with DAC
- 14. UK research-grade sourcing
- References
2. Molecular structure — full-length GHRH vs CJC-1295
Tesamorelin is [trans-3-hexenoyl]-hGHRH(1-44)-NH₂ — the 44-amino-acid native human GHRH sequence with a trans-3-hexenoyl (a C6 unsaturated acyl) group attached to the N-terminal tyrosine. Molecular weight 5196.00 Da. The hexenoyl group blocks DPP-4 cleavage at position 2 (Ala), which would otherwise be the primary inactivation pathway.
Comparison with other GHRH analogues:
- Sermorelin: GHRH(1-29), unmodified, 29 aa. Half-life 10-20 min. No longer widely used.
- CJC-1295 no-DAC: GHRH(1-29) with 4 aa substitutions. Half-life 25-30 min. Preserves pulsatility; supersedes sermorelin.
- CJC-1295 with DAC: Same as no-DAC plus maleimido-lysine tail for albumin conjugation. Half-life ~8 days as albumin conjugate. Tonic activation.
- Tesamorelin: Full-length GHRH(1-44) with hexenoyl N-terminal modification. Half-life ~30-40 min (plasma); biological effect duration 3-4 hours.
The key structural distinction: tesamorelin retains the full C-terminal domain (aa 30-44), which is absent from all CJC-1295 variants. The full-length structure may interact with additional GHRH receptor binding determinants that the 1-29 fragment does not engage, contributing to tesamorelin’s distinctive visceral-fat effect.
3. GHRH receptor pharmacology
Tesamorelin binds and activates the GHRH receptor with similar affinity to native GHRH. Signalling is standard class B GPCR: Gαs → adenylyl cyclase → cAMP → PKA → CREB → GH1 transcription and GH vesicle exocytosis.
A mechanistically relevant point: the GHRH receptor is expressed not only on pituitary somatotrophs but also at lower density on adipose tissue (both SAT and VAT), hepatic cells, and pancreatic cells. Whether direct peripheral GHRHR engagement contributes to tesamorelin’s VAT-selective effect, independent of IGF-1 mediation, is an active research question.
4. Pharmacokinetics
- Plasma half-life: ~26-38 min
- GH releasing effect duration: 3-4 hours
- Metabolism: peptide hydrolysis; no CYP involvement
- No clinically meaningful drug interactions identified
5. HIV-lipodystrophy pivotal trials
- IGF-1: tesamorelin +81%, placebo no change
- Waist circumference: tesamorelin −2.2 cm, placebo −0.5 cm
- VAT change: tesamorelin −10.9%, placebo −0.6%
- Similar lipid and IGF-1 response to Study 1
8. Cognitive and CNS research
A smaller body of research has examined tesamorelin in cognitive aging and mild cognitive impairment:
Baker et al, Arch Neurol 2012: 20-week tesamorelin trial in 152 adults (mean age 68) with normal cognition or mild cognitive impairment. Modest improvements in executive function and verbal memory domains, attributed to GH/IGF-1 effects on hippocampal and prefrontal function.
This research area remains exploratory but is mechanistically well-grounded: GHRH receptors are expressed in hippocampus, prefrontal cortex and cerebellum, and IGF-1 has established neuroprotective signalling.
10. Pulsatility preservation vs CJC-1295 with DAC
For research designs where pulsatility is important but longer action than sermorelin or CJC-1295 no-DAC is desired, tesamorelin occupies a useful intermediate pharmacokinetic niche.
14. UK research-grade sourcing
Tesamorelin should be sourced with full documentation:
- ≥98% HPLC purity (≥99% is the emerging 2026 standard)
- Mass spectrometry identity confirmation (theoretical MW 5196.00 Da)
- Batch-specific Certificate of Analysis
- Endotoxin quantification
- Residual TFA analysis
- Lyophilised powder with cold-chain shipping
Quality-control specific note: the trans-3-hexenoyl N-terminal modification is the distinguishing synthetic step. A high-quality COA should specifically address the acylation yield and confirm the absence of des-hexenoyl parent peptide (which would be rapidly DPP-4-inactivated and pharmacologically inactive).
Limits of the evidence
Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.
Laboratory handling
- Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
- Let vials reach room temperature before opening to limit condensation.
- Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
- Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
- Use the peptide calculator for concentration arithmetic (mg/mL).
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359–2370.
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab 2010;95:4291–4304.
- Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821–e830.
- Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012;69:1420–1429.
- Ferdinandi ES et al. Nonclinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007;100:49–58.
- Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 2015;25:59–65.
- Adrian S et al. The growth hormone releasing hormone (GHRH) receptor antagonist and GHRH agonist tesamorelin: a review. Endocr Metab Immune Disord Drug Targets 2017;17:66–75.
- Sinha DK et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition. Transl Androl Urol 2020;9(Suppl 2):S149–S159.
- Kineman RD et al. Understanding the physiology of growth hormone-releasing hormone and growth hormone-releasing peptide action. Front Endocrinol 2011;2:24.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45–53.
UK Research Cluster Hubs
- GLP-1 Research Hub
- Tirzepatide Hub
- Retatrutide Hub
- BPC-157 Research Hub
- TB-500 Research Hub
- Growth-Hormone Peptides Hub
- Research-Grade Buyer’s Guide
Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.
For laboratory research use only. Tesamorelin sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.
